Search: onr:"swepub:oai:DiVA.org:liu-49949" >
Long-term follow-up...
-
Wilking, N.Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden
(author)
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
- Article/chapterEnglish2007
Publisher, publication year, extent ...
-
Elsevier BV,2007
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-49949
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-49949URI
-
https://doi.org/10.1093/annonc/mdl488DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-22781URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-105521URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:12450047URI
-
https://lup.lub.lu.se/record/670294URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below theage of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb group, respectively [P = 0.074, hazard ratio (HR) 0.804, 95% confidence interval (CI) 0.633-1.022]. Ten patients in the tailored FEC regimen developed acute myeloid leukaemia (AML)/myelodysplasia (MDS). One hundred deaths occurred in the tailored FEC group and 121 in the CTCb group (P = 0.287, HR 0.866, 95% CI 0.665-1.129). Conclusion: The update of this study shows an improved outcome linked to the tailored FEC treatment in relation to breast cancer relapse, but also an increased incidence of AML/MDS. © 2007 Oxford University Press.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Lidbrink, E.Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden
(author)
-
Wiklund, T.Roche OY, Espoo, Finland, Department of Oncology, University Hospital, Helsinki, Finland
(author)
-
Erikstein, B.Southern Norway Regional Health Authority, Skien, Norway, The Norwegian Radiumhospital, Oslo, Norway
(author)
-
Lindman, HenrikUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Department of Oncology, Akademiska Hospital, Uppsala, Sweden(Swepub:uu)henrlind
(author)
-
Malmström, PerLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Malmström, P., Department of Oncology, University Hospital, Lund, Sweden(Swepub:lu)onk-pma
(author)
-
Kellokumpu-Lehtinen, P.Department of Oncology, Tampere University, University Hospital, Tampere, Finland
(author)
-
Bengtsson, N.-O.Umeå universitet,Institutionen för strålningsvetenskaper,Department of Oncology, University Hospital, Umeå, Sweden,Department of Oncology, Ryhov Hospital, Jönköping, Sweden
(author)
-
Söderlund, G.Östergötlands Läns Landsting,Onkologiska kliniken US
(author)
-
Anker, G.Department of Oncology, Haukeland University Hospital, Bergen, Norway, Department of Oncology, Haukeland Hospital, Bergen, Norway,Department of Hematology, Karolinska Hospital, Stockholm, Sweden,Department of Oncology, Gävle Hospital, Gävle, Sweden
(author)
-
Wist, E.Department of Oncology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway, Department of Oncology, Regional Hospital, Tromsø, Norway
(author)
-
Ottosson, S.Department of Oncology, NÄL, Trollhättan, Sweden,Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
(author)
-
Salminen, E.Department of Oncology, Turku University Hospital, Turku, Finland
(author)
-
Ljungman, P.Karolinska Institutet,Haematology Centre, Karolinska University Hospital, Stockholm, Sweden, Department of Hematology, Huddinge Hospital, Stockholm, Sweden
(author)
-
Holte, H.Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway, Hematology Section, The Norwegian Radiumhospital, Oslo, Norway,Mälarsjukhuset Eskilstuna of Oncology, Borås Hospital, Borås, Sweden,Department of Oncology, Ullevål Hospital, Oslo, Norway
(author)
-
Nilsson, J.Trial Form Support AB, Stockholm, Sweden
(author)
-
Blomqvist, C.Department of Oncology, University Hospital, Helsinki, Finland
(author)
-
Bergh, J.Karolinska Institutet,Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden
(author)
-
Hoglund, M.Höglund, M., Department of Hematology, University Hospital, Uppsala, Sweden
(author)
-
Bengtsson, M.Department of Clinical Immunology, University Hospital, Uppsala, Sweden
(author)
-
Gruber, A.Department of Hematology, Karolinska Hospital, Stockholm, Sweden
(author)
-
Fornander, T.Department of Oncology, Södersjukhuset,, Stockholm, Sweden
(author)
-
Petterson-Skold, D.Petterson-Sköld, D., Department of Oncology, Danderyd Hospital, Stockholm, Sweden
(author)
-
Lofvenberg, E.Löfvenberg, E., Department of Hematology, University Hospital, Umeå, Sweden
(author)
-
Villman, K.Department of Oncology, Örebro Hospital, Örebro, Sweden
(author)
-
Karlsson, KatarinaLinköpings universitet,Hälsouniversitetet,Omvårdnad,Department of Internal Medicine, University Hospital, Turku, Finland(Swepub:liu)katka12
(author)
-
Hultborn, R.Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
(author)
-
Ottoson, S.Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
(author)
-
Mattson, J.Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden,Department of Hematology, Ullevål Hospital, Oslo, Norway
(author)
-
Jansson, S.Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden
(author)
-
Braide, I.Department of Hematology, Sahlgrenska Hospital, Göteborg, Sweden
(author)
-
Carlsson, G.Department of Oncology, Östra Hospital, Göteborg, Sweden
(author)
-
Rodjer, S.Rödjer, S., Department of Hematology, Östra Hospital, Göteborg, Sweden
(author)
-
Sallerfors, B.Department of Hematology, University Hospital, Lund, Sweden
(author)
-
Ahlgren, J.Department of Oncology, Gävle Hospital, Gävle, Sweden
(author)
-
Gawelin, A.Department of Oncology, Gävle Hospital, Gävle, Sweden
(author)
-
Solderberg, M.Sölderberg, M., Department of Oncology, Karlstad Hospital, Karlstad, Sweden
(author)
-
Hansen, J.Department of Oncology, Västerås Hospital, Västerås, Sweden
(author)
-
Stenstam, B.Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden
(author)
-
Svensson, J.-H.Mälarsjukhuset Eskilstuna of Oncology, Borås Hospital, Borås, Sweden
(author)
-
Norberg, B.Department of Oncology, Ryhov Hospital, Jönköping, Sweden
(author)
-
Kvalheim, G.Department of Medicine, The Norwegian Radiumhospital, Oslo, Norway
(author)
-
Sommer, H.H.Department of Oncology, Ullevål Hospital, Oslo, Norway
(author)
-
Tangen, J.M.Department of Hematology, Ullevål Hospital, Oslo, Norway
(author)
-
Lundgren, S.Department of Oncology, Regional Hospital, Trondheim, Norway
(author)
-
Remes, K.Department of Internal Medicine, University Hospital, Turku, Finland
(author)
-
Lehtinen, M.Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland
(author)
-
Koivinen, E.Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland
(author)
-
Turpeenniemi-Hujanen, T.Department of Oncology, Oulu University Hospital, Oulu, Finland
(author)
-
Kuittinen, O.Department of Oncology, Oulu University Hospital, Oulu, Finland
(author)
-
Voutilainen, L.Department of Oncology, Kuopio University Hospital, Kuopio, Finland
(author)
-
Mirza, M.R.Department of Oncology, University Hospital, Odense, Denmark
(author)
-
Rose, C.Department of Oncology, University Hospital, Odense, Denmark
(author)
-
Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, SwedenRadiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden
(creator_code:org_t)
Related titles
-
In:Annals of Oncology: Elsevier BV18:4, s. 694-7000923-75341569-8041
Internet link
Find in a library
To the university's database
- By the author/editor
-
Wilking, N.
-
Lidbrink, E.
-
Wiklund, T.
-
Erikstein, B.
-
Lindman, Henrik
-
Malmström, Per
-
show more...
-
Kellokumpu-Lehti ...
-
Bengtsson, N.-O.
-
Söderlund, G.
-
Anker, G.
-
Wist, E.
-
Ottosson, S.
-
Salminen, E.
-
Ljungman, P.
-
Holte, H.
-
Nilsson, J.
-
Blomqvist, C.
-
Bergh, J.
-
Hoglund, M.
-
Bengtsson, M.
-
Gruber, A.
-
Fornander, T.
-
Petterson-Skold, ...
-
Lofvenberg, E.
-
Villman, K.
-
Karlsson, Katari ...
-
Hultborn, R.
-
Ottoson, S.
-
Mattson, J.
-
Jansson, S.
-
Braide, I.
-
Carlsson, G.
-
Rodjer, S.
-
Sallerfors, B.
-
Ahlgren, J.
-
Gawelin, A.
-
Solderberg, M.
-
Hansen, J.
-
Stenstam, B.
-
Svensson, J.-H.
-
Norberg, B.
-
Kvalheim, G.
-
Sommer, H.H.
-
Tangen, J.M.
-
Lundgren, S.
-
Remes, K.
-
Lehtinen, M.
-
Koivinen, E.
-
Turpeenniemi-Huj ...
-
Kuittinen, O.
-
Voutilainen, L.
-
Mirza, M.R.
-
Rose, C.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Annals of Oncolo ...
- By the university
-
Linköping University
-
Umeå University
-
Uppsala University
-
Karolinska Institutet
-
Lund University